| Dr Sean Raymond Legler, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Dr Sean Raymond Legler |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 6 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750878435 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 68793 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
News Archive
Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).
The genes that make up the immune system of the Aedes aegypti mosquito which transmits deadly viral diseases to humans have been identified in new research in Science.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
Schoolchildren who required surgery as infants for congenital heart disease (CHD) run a significant risk of having problems with inattention and hyperactivity, and often require remedial services in school.
› Verified 2 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).
The genes that make up the immune system of the Aedes aegypti mosquito which transmits deadly viral diseases to humans have been identified in new research in Science.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
Schoolchildren who required surgery as infants for congenital heart disease (CHD) run a significant risk of having problems with inattention and hyperactivity, and often require remedial services in school.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sean Raymond Legler, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Dr Sean Raymond Legler, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).
The genes that make up the immune system of the Aedes aegypti mosquito which transmits deadly viral diseases to humans have been identified in new research in Science.
At last week's ABC-WIN Seminar, Prof. Dr. Michael Knauth, Director of Neuroradiology, University Hospital of Goettingen, Goettingen, Germany, and President-elect of the German Society of Neuroradiology, presented the European evaluation data on Separator 3D, a next-generation clot engagement device that works in conjunction with aspiration at the site of the lesion causing an acute ischemic stroke to remove the clot and restore blood flow to affected brain tissue.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
Schoolchildren who required surgery as infants for congenital heart disease (CHD) run a significant risk of having problems with inattention and hyperactivity, and often require remedial services in school.
› Verified 2 days ago
Christopher P Mccoy, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Thomas Kingsley, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Alexander Ryu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Xiao Jing Wang, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Nichole Elizabeth Brunton, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Tuoyo Mene-afejuku, MD, MPH Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Bright Pearson Thilagar, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |